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ABSTRACT ~_~ _
Although a number of clinical trials are available esti-
mating the benefits of lipid-lowering therapies that in-
clude economic end-points, development of modeling
methodologies are essential to extend results of those
trials over time and to other populations. We reviewed
the key issues to be considered when extending trial data
to real-world situations. The availability of recent ran-
domized controlled trials of 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase inhibitors in
primary and secondary prevention has demonstrated the
limitations of earlier modeling efforts to project benefits
of lipid modification. The importance of risk stratifica-
W ith an increasing number of clinical trials esti-mating the benefits of lipid-lowering therapies
that include economic end-points, some concerns
have been raised with respect to the usefulness of
economic modeling. The development of modeling is
essential to extend results of clinical trials beyond the
limited time horizon of the trial, although the proper
extension of results beyond clinical trials requires re-
considering previous axioms in light of new under-
standing of the underlying disease processes.
Economic Modeling and Clinical Trials
There is a selection process in recruiting subjects
for a clinical trial that implies that some groups,
such as women and the elderly, are excluded from
the study population. Although coronary heart
disease (CHD) is a major concern for people over
the age of 65, only one economic evaluation has
reported on subjects in the 65-85-year-old age
group [1]. Previously published analyses of the
Scandinavian Simvastatin Survival Study (4S) study
suggested that subjects 65-70 years old had simi-
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tion is demonstrated, particularly the importance of
both LDL and HDL cholesterol either together or as a
ratio measure. The selection of modeling methodology to
extend benefits of a treatment beyond the end of a trial
and over a lifetime is discussed. The relationship between
benefits from lipid reduction and risk difference is de-
scribed, demonstrating that for individuals with estab-
lished coronary heart disease (CHD) and those older
than age 58, benefits from lipid reduction are greater
than those predicted from baseline lipid-related risk dif-
ferences alone. The implications of these data for pri-
mary prevention of CHD in the elderly are discussed.
lar relative benefits of lipid-lowering therapy to
those under 65 years of age, in terms of CHD
mortality, all-cause CHD, or revascularization [2].
So far, the limited data available suggest that there
are no obvious differences in lipid therapy benefits
to be gained by subjects under 65 compared with
older individuals. However, the issue of age re-
mains important, especially in view of one of the ear-
liest conclusions from the projection of Framingham
Heart Study models that lipid-lowering therapy in
the elderly might not be extremely effective [3}.
In extending clinical trial results to other popula-
tions, a central axiom has been the distinction be-
tween primary and secondary prevention. This has
traditionally been based on whether individuals
have had a previous CHD event (secondary) or not
(primary). However, depending upon age, some or
many patients thought to be receiving primary pre-
vention already have the (subiclinical disease, ath-
erosclerosis, although they have not had a throm-
bosis upon plaque rupture (a CHD event). Recent
understanding of the role of subclinical disease as a
risk factor for subsequent CHD and its relationship
to benefits from lipid reduction requires that we re-
think both the boundary of primary/secondary pre-
vention, as well as which trials are applicable for
extension to particular patient groups.
The substantial practice variation with respect
to management of CHD, in particular revascular-
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ization, makes the location of a clinical trial an
important determinant of the economic outcomes
of the intervention. This can bias subsequent eco-
nomic analyses. Although sensitivity analyses of
price inputs are widely used to allow health main-
tenance organizations (HMOs) to use their own
prices, the actual determinants of the economic
consequences of CHD are more related to the re-
gion or country where the study is conducted
rather than to the actual input price of the drug
used or surgery performed. This is particularly im-
portant to consider when examining joint out-
comes such as economic outcomes and clinical
events. The probability of having a certain out-
come, such as revascularization, depends almost
as much on where the study was conducted as it
does on actual treatment.
Extending Clinical Trial Data to
Other Populations
Risk factor profiles can be developed to identify a
population in a clinical trial and then to extend
data for this population to subjects outside the
trial with the same set of risk factors. In this pro-
cess, the following key issues have to be taken into
consideration: 1) the importance of cholesterol
history over time, and 2) the selection of the mea-
sure to be used to stratify the population and im-
pute effects.
Importance of Prior Lipid Exposure and Age
When examining a measure of atherosclerosis-
carotid stenosis-in men in the Framingham
Heart Study at a given time (exam 20), there was a
clear linear relationship between cholesterol level
8 years before (exam 15) and current extent of
atherosclerosis. However, there was no relation-
ship between current cholesterol level and current
extent of atherosclerosis [4]. This same lack of as-
sociation between current lipid levels for older
persons and carotid stenosis has been found in the
Cardiovascular Health Study for both men and
women [5].
In addition to the importance of prior rather
than current lipid levels to identify risk in older in-
dividuals, there is evidence from current clinical
trials that older individuals obtain greater benefits
from lipid reduction than would be predicted
from differences in risk associated with their pre-
and post-treatment lipid levels alone. To illustrate
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the age issue, we used data from the Lipid Re-
search Clinics Coronary Primary Prevention Trial
(CPPT) [6]. We examined actual events and pre-
dicted CHD events by age [7]. After evaluating the
change in lipid measures for 2 months, 6 months, 1
year, and 2 years as a predictor of subsequent CHD
risk, we found the change over the initial 2 months
to be a superior predictor compared to longer ob-
servation periods [8]. For the placebo group, we
based our predictions on the 2-month change in
lipid values and calculated event rates over a 7-year
period using a risk equation. In this case, with lit-
tle change in lipid levels, predictions were accurate
and close to what actually happened in the pla-
cebo group. For the treated group, greater risk re-
ductions were predicted for younger age groups
than were actually achieved. Predictions for the
mean age group were close to event rates observed
during the trial, whereas risk reduction for sub-
jects over the age of 55 was underpredicted, The
crossover point was about the mean age for the
trial.
Fractions of maximum benefit for each age
group were estimated by differences between pre-
dictions and actual risk reduction. The mean
CPPT results perfectly validated the risk equation
for mean age population group. However, frac-
tion of maximum benefit for older individuals
were substantially greater than one and in many
cases closer to two, while fractions of benefit for
younger individuals were 80% or less. Hence,
models that use equations validated only on the
mean trial result suggest that treatments are more
cost-effective for younger patients and less cost-
effective for older patients. In reality, benefits are
probably overestimated for younger individuals
and underestimated for older individuals [1,3,9].
Identification of Subjects Who Need
Lipid-Lowering Therapy
Clinical studies are designed, as much as possible,
to recruit high-risk individuals. Elevated low den-
sity lipoprotein (LDL) cholesterol levels are cur-
rently used to identify subjects who need lipid-
lowering therapy, with the sole objective of reduc-
ing LDL cholesterol levels [10]. However, a num-
ber of measures can be used to identify high-risk
persons (LDL cholesterol levels, high density lipo-
protein [HDL] cholesterol levels, total cholesterol
levels, and ratios of these elements) and to esti-
mate the benefits of a lipid-lowering therapy
(changes in lipid levels or changes in ratios). Re-
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cent analyses have challenged these LDL-based
guidelines [11,12].
When examining CHD risks (CHD death and
myocardial infarction [MIll for the 4S population
using either the LDL stratification or the LDLI
HDL ratio stratification across 10 deciles, it is ap-
parent that, compared with the LDL stratification,
where risks are consistent across the deciles, per-
haps 20% of the 45 population is at relatively low
risk of a CHD event when stratified using the
LDLlHDL ratio [II). Thus, the risk pool could be
enhanced by using a superior measure of baseline
stratification in future studies, such as the LDLI
HDL ratio.
Second, the risk relationship between LDL and
risk in the placebo group is relatively flat, rising
from 23-32% across the LDL distribution. When
moving a subject with a higher cholesterol level to
a lower level on such a curve, the projected risk re-
duction is relatively low, in contrast to the risk re-
duction actually observed. As with the CPPT data
for older persons, in 4S the risk reduction ob-
served is 30-100% greater than that predicted
from the baseline risk relationship, estimated on
the trial data with the traditional Framingham
risk model.
In the accompanying technical article [13], we
demonstrate that, by using data from the Framing-
ham Heart Study and the Coronary Primary Pre-
vention Trial (which used cholestyramine as the
lipid-lowering agent and nonpharmacological meth-
ods to raise HDL), TCIHDL and LDLIHDL ratio
measures are superior to LDL or changes in LDL
alone as predictors of risk and risk reduction from
lipid-modifying therapy.
Beyond those stratified analyses, when we used
multivariate models to determine the effects of
changes over 7-year events in LDL and changes in
HDL cholesterol on the odds of a CHD event for
the CPPT population, changes in HDL cholesterol
were approximately equal and opposite to changes
in LDL cholesterol. A 10% increase in HDL low-
ered risk by about 20%, whereas a 10% increase
in LDL increased it by about 20%. For both LDLf
HDL and total cholesterol (TC)IHDL ratios, a 20-
25% increase in risk was obtained for every 10%
increase in the lipid measure [8). It is thus surpris-
ing that LDLlHDL or total cholesterollHDL ratios
have not been used extensively to identify patients
suitable for lipid-lowering therapy, nor as predic-
tors of the benefits of that therapy [2,14). However,
recent analyses from the 4S and West of Scotland
Coronary Prevention Study (WOSCOPS) groups in-
dicate that the level of HDL, and changes in TC/
183
HDL ratio in 4S are potent predictors of risk and
benefit, respectively [15,16].
Extending Clinical Trials over Time
Extension of the benefits of a therapy beyond the
end of a trial is particularly important when one is
contemplating life-long therapy. For analyses of
clinical trials, years of life gained is a common
outcome used in the denominator of a cost-effec-
tiveness ratio. However, this ratio can be calcu-
lated in two ways-either as the difference in the ob-
served or projected survival curves at a particular
time, or as the difference in event rates at a partic-
ular time-and then used to estimate a difference
in years of life gained. That is, life-years lost are
treated as a "price," attached to the observed dif-
ference in event rates. Thus, if an MI "costs" 2.5
years of life expectancy, then 10 fewer MIs in the
treated group should gain 25 additional life-years.
While the two methods should yield similar esti-
mates of years of life gained for a lifetime projec-
tion, the latter method underestimates the cost of
the intervention, which is taken from the within-
trial period.
The other caution is that different functional
forms of a risk equation will yield different esti-
mates of risks and projected treatment effects. Us-
ing a Weibull distribution to estimate the survival
function from the 4S trial, we projected the life-
time cost-effectiveness of lipid-lowering treatment
to be from $5000 to $9000 per year of life saved,
and the within-trial cost-effectiveness ratio to be
between $18,000 and $26,000 per year of life
saved. The upper 95% confidence interval crosses
$50,000 per year of life saved for both of the
within-trial analyses. However, when stratified by
the TCIHDL ratio, those individuals in the highest
tertile of the TCIHDL ratio in the 4S study had a
within-trial cost-effectiveness ratio upper bound
less than $50,000 per year of life saved. The same
was not found for those individuals in the upper
tertile of LDL cholesterol.
We have estimated a similar model for primary
prevention, using the Coronary Primary Preven-
tion Trial, The model is detailed in another paper
[17], with incremental cost-effectiveness ratios
(CER) reported for niacin, lovastatin, fluvastatin,
and colestipol. The CERs for niacin, fluvastatin,
and lovastatin were all within $50,000 per year of
life gained, in contrast to previous projections of pri-
mary prevention. The differences from earlier mod-
els come from using direct treatment estimates-
which exceed the assumed maximum benefit of
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older models-so that the projected outcomes
more accurately represent experience of treating
individuals with lipid-modifying therapy. We have
also performed an incremental frontier analysis,
indicating that niacin is the most efficient agent,
even with a low compliance rate, if a statin is used
for individuals incapable of tolerating niacin.
New Risk Factors, New Paradigms, and
Primary Prevention
Recent evidence indicates that measures of sub-
clinical disease are potent risk factors for subse-
quent CHD events over a 3-5-year horizon [5]. Ca-
rotid ultrasound, ankle-arm index, resting EKG, or
Rose-questionnaire angina were used as markers
for subclinical disease in a population-based sam-
ple of over 5000 Medicare beneficiaries in the
Cardiovascular Health Study. Subjects with sub-
clinical disease based on these measures had rela-
tive risks of 3-year CHD events from two to three
times those of individuals without subclinical dis-
ease. The same kind of discrimination is observed
in women, although actual 3-year event rates are
substantially lower. Hence, measures of subclini-
cal atherosclerosis appear to be good predictors of
CHD events.
The importance of subclinical disease is empha-
sized when one evaluates studies of patients with
MIs who had a cardiac catheterization within a
year of their MI. In those studies, only 15-30% of
infarcts occurred in vessels with at least a 70% le-
sion, while from 30-60% of MIs occurred in indi-
viduals who had less than 50% lesions in infarct-
related vessels. Thus, rupture of vulnerable plaque,
rather than progressive stenosis of an artery, is re-
sponsible for the majority of MIs. This might ex-
plain why, in the 4S [2] and West of Scotland [14]
trials, lipid therapy-which stabilizes the early,
vulnerable, lipid-rich plaques prone to rupture-is
so effective at preventing future CHD events in a
relatively short time, whereas the trials of bypass
surgery have not reduced MI rates. If so, subclini-
cal disease may prove a more potent discriminator
for targeting lipid-lowering therapy.
Fitting the Model to the Elderly
Finally, an important issue to take into consider-
ation is the extension of a model to the elderly.
While previous models using the observational as-
sumptions of maximum benefit have suggested lit-
tle benefit from lipid reduction in the elderly,
those assumptions do not appear valid when tested
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against clinical trial results [2,6,14]. When one
compares the risk curves for CHD events as a func-
tion of lipid measure (either LDL or TCIHDL ra-
tio), one notices that, although relative risk declines
with age, it is because the absolute risks rise among
older individuals at progressively lower levels of the
lipid measure used. Thus, the risk difference be-
tween those with higher and lower levels of the
lipid measure declines (seen as a declining relative
risk) [7]. This "smoothing out" of CHD risk across
the lipid range must be combined with the knowl-
edge of subclinical disease, the role of subclinical
atherosclerosis in causing subsequent coronary
events, the importance of the history of cholesterol
exposure in defining the risk of CHD, and preva-
lence measures of subclinical disease in the elderly
(ranging from 60% among those with "ideal" LDL
to 66% among those with elevated LDL). Combin-
ing these observations, it appears that the effects of
lowering lipids in the elderly are better predicted by
projections based on a secondary prevention model
(i.e., preventing further disease, given the disease of
atherosclerosis) rather than a primary prevention
model (i.e., preventing clinical events, assuming no
prior clinical events as the definition of "disease").
Conclusions
In conclusion, the proper extension of results be-
yond clinical trials to larger populations requires
accurate transportable measures and models. Un-
fortunately, most of the studies reported so far have
not performed validations to examine whether these
requirements are fulfilled. Ratio measures are su-
perior to LDL cholesterol as discriminators of CHD
risk. Measures of subclinical atherosclerosis might
be superior markers for preventive treatments than
lipid measures, particularly in the elderly. Primary
prevention in the elderly more closely models sec-
ondary prevention than it does primary preven-
tion. From an economic point of view, practice
variation probably has more impact on cost-effec-
tiveness ratios than input prices [18]. Estimates of
cost-effectiveness ratios with a directly modeled
intervention are superior to, and should replace,
guidelines based on earlier observational models.
This article was prepared with the assistance of BioMed-
Com Consultants inc.,Montreal, Canada.
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